SEC Form 4 · accession 0001140361-18-026731
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Sulpizio
Director
Period of report
May 30, 2018
Accepted (ET)
Jun 1, 2018 · 12:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | May 30, 2018 | M | 28,403 | $27.58 | A | 35,823 | D | |
| ResMed Common StockF1 | May 30, 2018 | S | 28,403 | $102.78 | D | 7,420 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF2 | $27.58 | May 30, 2018 | M | 28,403 | D | Nov 11, 2014 | Nov 16, 2018 | ResMed Commmon Stock | 28,403 | 0 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $102.48 to $103.17. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.
- F2Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date.